SCH79797 dihydrochloride,PAR1拮抗剂(ab120858)
Key features and details
- Potent and selective PAR1 antagonist
- CAS Number: 1216720-69-2
- Purity: > 98%
- Soluble in DMSO to 50 mM and in ethanol to 10 mM
- Form / State: Solid
- Source: Synthetic
概述
-
产品名称
SCH79797 dihydrochloride,PAR1拮抗剂 -
描述
Potent and selective PAR1拮抗剂 -
生物学描述
Potent and selective non-peptide Proteinase-Activated Receptor-1 (PAR1) antagonist (IC50 = 70 nM). Protects against ischemic injury. Additionally induces apoptosis and inhibits cell proliferation.
-
纯度
> 98% -
CAS编号
1216720-69-2 -
化学结构
性能
-
化学名称
N3-Cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine dihydrochloride -
分子量
444.41 -
分子式
C23H25N5.2HCl -
PubChem识别号
45073452 -
存放说明
Store at Room Temperature. Store under desiccating conditions. The product can be stored for up to 12 months. -
溶解度概述
Soluble in DMSO to 50 mM and in ethanol to 10 mM -
处理
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CC(C)C1=CC=C(C=C1)CN2C=CC3=C2C=CC4=C3C(=NC(=N4)NC5CC5)N.Cl.Cl -
来源
Synthetic
-
研究领域
实验方案
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
文献 (2)
ab120858 被引用在 2 文献中.
- Zhou LX et al. Blood-nerve barrier disruption and coagulation system activation induced by mechanical compression injury participate in the peripheral sensitization of trigeminal neuralgia. Front Mol Neurosci 15:1059980 (2022). PubMed: 36618827
- Miao D et al. Platelets are activated in ANCA-associated vasculitis via thrombin-PARs pathway and can activate the alternative complement pathway. Arthritis Res Ther 19:252 (2017). PubMed: 29141676